Acquisition by Richard Adcock of 8620 shares of Immunitybio subject to Rule 16b-3
| IBRX Stock | USD 5.10 0.02 0.39% |
Slightly above 54% of Immunitybio's investor base is interested to short. The analysis of overall sentiment of trading Immunitybio stock suggests that many investors are impartial at this time. Immunitybio's investing sentiment can be driven by a variety of factors including economic data, Immunitybio's earnings reports, geopolitical events, and overall market trends.
Immunitybio |
Filed transaction by Immunitybio Officer Ceo President. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Immunitybio Fundamental Analysis
We analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Immunitybio is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Immunitybio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunitybio stock to make a market-neutral strategy. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics with similar companies.
Peers
Immunitybio Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| ARDX | Ardelyx | 6.36 | ||||
| CVAC | CureVac NV | 4.74 | ||||
| MCRB | Seres Therapeutics | 4.55 | ||||
| BLRX | BioLineRx | 3.57 | ||||
| VIR | Vir Biotechnology | 3.15 | ||||
| TGTX | TG Therapeutics | 2.16 | ||||
| VKTX | Viking Therapeutics | 2.04 | ||||
| PDSB | PDS Biotechnology | 1.90 | ||||
| PLX | Protalix Biotherapeutics | 0.60 | ||||
| KRYS | Krystal Biotech | 0.20 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.57 | ||||
| ELEV | Elevation Oncology | 1.59 | ||||
| LXRX | Lexicon Pharmaceuticals | 2.44 |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.